The vascular endothelium plays an important role in the regulation of vascular tone by releasing several vasoactive substances, such as nitric oxide (NO), and endothelial dysfunction underlying several vascular pathological conditions has been ascribed to either reduced NO release from the endothelial cells or reduced bioavailability of NO. Indeed, a decrease in the bioavailability of endothelium-derived NO has been demonstrated in patients with cardiovascular risk factors and Quyyumi et al have suggested that the basal activity of NO is reduced in the human atherosclerotic epicardial and microvascular coronary arteries. Decreased release of NO has been also reported to contribute to the increased basal tone at the coronary arterial spastic site in patients with vasospastic angina (VSA). In support of these recent findings, we recently reported that the coronary sinus – arterial (V–A) difference of NOx and ADMA was observed in patients with VSA, but not in those of the control. Higher ADMA concentrations might cause the reduced formation of NO that underlies the pathophysiology of coronary vasospasm. 

Key Words: Asymmetric dimethylarginine; Coronary circulation; Vasospasm
ergonovine maleate. They had angiographically normal or nearly normal coronary arteries.

**Vasospastic Angina Group (VSA Group)** This group consists of comprised 15 men and 1 woman whose mean age was 58±12 years old (range, 27–76). All these patients with VSA showed angiographic coronary artery spasm associated with ischemic ST-segment changes with chest pain after intracoronary injection of ergonovine maleate, but none had significant organic stenosis (>50% reduction in luminal diameter).

None of the study subjects had a history of myocardial infarction, valvular heart disease, congenital heart disease, peripheral arterial disease, renal dysfunction, or other serious diseases. The study protocol was approved by the Niigata University Hospital Ethics Committee. Written informed consent was obtained from each patient before cardiac catheterization. The major coronary risk factors (ie, hypertension, hypercholesterolemia [serum total cholesterol >220 mg/dl], diabetes mellitus and smoking) of the 2 groups were assessed.

**Study Protocol**

Anti-anginal drugs were discontinued at least 48 h before cardiac catheterization and although the use of sublingual nitroglycerin was to be permitted if needed, none of the patients used it in the 6 h before catheterization. All patients received underwent routine pressure and volume studies. Before coronary angiography, a sidewinder catheter was introduced into the coronary sinus and blood samples were obtained simultaneously from both the coronary sinus and the ostium of the left coronary artery. Thereafter, coronary arteriography was performed using the Judkin’s technique as described previously.13 Coronary arteriograms were recorded using a Philips cineangiography system (Integris H3000). The distances from the X-ray focus to the patient, and that from the patient to the image intensifier, were kept constant during the study. After the baseline coronary arteriogram had been recorded, ergonovine was infused at 103/g/min until vasospasm was provoked or until the maximal dose of 50μg had been given. In this study, coronary spasm was defined as total or subtotal occlusion of the epicardial coronary arteries associated with signs of myocardial ischemia, such as chest pain, and ischemic ST-segment changes. When chest pain or significant ST-segment deviations occurred, coronary angiography was performed immediately. If coronary artery spasm was confirmed, isosorbide dinitrate (ISDN) was administered into the left coronary artery until the coronary spasm was relieved. If not, all patients in whom coronary artery spasm was not confirmed routinely received an intracoronary injection of ISDN (2 mg). The heart rate, arterial pressure and a 12-lead electrocardiogram were monitored continuously.

**Quantitative Coronary Angiography** Quantitative assessment of the coronary arterial luminal diameter of the coronary artery was performed using a computer-assisted quantitative cardiac analyzer (CAM-1000, Nishimoto Sangyo Inc, Osaka, Japan). The luminal diameter was analyzed in the right anterior oblique position at end-diastole. For the VSA patients, we measured the luminal diameter of the left coronary artery in which the focal spasm was provoked (spasm site). In addition, the luminal diameters were measured at the proximal and distal segments of the left anterior descending coronary artery (LAD) and left circumflex artery (LCx) in both groups. The luminal diameter of the LAD was measured at the arterial origin (proximal) and at the point of half of the distance from way between the first major septal branch and the apex of the heart (distal). The diameter of the LCx was also measured similarly at the origins (proximal) of the artery and of the posterolateral branch (distal). The size of the Judkin’s catheter was used for calibrating the arterial diameter in millimeters.

The inter and intra-observer reproducibility of the measurements using this quantitative system were acceptable (r=0.96, SEE=0.16 mm, p<0.001; and r=0.98, SEE=0.11 mm, p<0.001, respectively). The basal coronary artery tone (% dilatation after ISDN) was calculated as:

\[ \text{Basal coronary artery tone (\%)} = \left(\frac{\text{Diameter after ISDN} - \text{Diameter before ISDN}}{\text{Diameter before ISDN}}\right) \times 100 \]

**Measurement of Nitrite (NO\textsubscript{2}–) and Nitrate (NO\textsubscript{3}–) Concentrations in Blood** The blood samples obtained from the coronary sinus and the ostium of the left coronary artery were immediately heparinized (20 U/ml, final concentration) and centrifuged (3,000 rpm at 4°C for 5 min). The plasma was mixed with methanol (1:1 v/v), and centrifuged at 10,000 g at 4°C for 10 min to remove the protein. The supernatant was stored at −80°C until analyzed. The NO\textsubscript{2}– and NO\textsubscript{3}– in the sample (100μl) were separated and quantified using a high-performance liquid chromatography (HPLC)-Griess system (ENO-10, EICOM, Kyoto, Japan), and the detection limit and the sensitivity of the system were both 100 nmol/L with a loading volume of 10μl.14 The low concentration of heparin used had no appreciable effect on the quantification of NO\textsubscript{2}– and NO\textsubscript{3}–. Each determination was performed in triplicate and NO\textsubscript{X} contamination arising from laboratory ware was actively excluded.15 The mean±SEM and coefficient of variance (in parenthesis) for the intra-assay and inter-assay of pooled plasma for NO\textsubscript{2}– were 0.14±0.01 μmol/L (7.7%) and 0.12±0.01 μmol/L (9.6%), respectively, and those for NO\textsubscript{3}– were 29.62±0.04 μmol/L (0.33%) and 29.33±0.06 μmol/L (0.47%).

**Measurement of ADMA Concentrations** The concentration of plasma ADMA was measured at SRL (Hachioji, Tokyo, Japan) by HPLC (Hitachi L-7480 system equipped with a fluorescence detector for excitation at 348 nm and emission at 450 nm with an ODS column) using orthophthalaldehyde (OPA) for fluorescence determination.16 The mean±SD and coefficient of variance for the intra-assay and inter-assay for ADMA (pooled human plasma) were 0.45±0.013 μmol/L (2.9%) and 0.456±0.011 μmol/L (2.4%), respectively.

| Table 1 Clinical Characteristics of the Study Patients |
|-----------------|-----------------|-----------------|
|                 | Control group   | VSA group       |
|                 | (n=16)          | (n=16)          |
| Age (years)     | 58±12           | 58±12           |
| M/F             | 13/3            | 15/1            |
| Total serum cholesterol (mg/dl) | 208±37        | 190±27          |
| LDL cholesterol (mg/dl)      | 130±41        | 110±24          |
| HDL cholesterol (mg/dl)      | 54±18         | 49±14           |
| Serum triglycerides (mg/dl)   | 105±32        | 134±54          |
| Current smoker            | 12 (75%)      | 13 (81%)        |
| Hypertension             | 4 (25%)        | 3 (19%)         |
| Diabetes mellitus        | 7 (44%)        | 9 (56%)         |

Values are expressed as mean±SD. HDL, high-density lipoprotein; LDL, low-density lipoprotein; VSA, vasospastic angina. *p=NS for all comparisons.
Statistical Analysis

The NOx (V–A) difference was calculated from the NOx concentrations in the arterial blood collected from the ostium of the left coronary artery (NOxA) and that of the venous blood collected at the coronary sinus (NOxV):

\[ \text{NOx (V–A) difference} = \text{NOxV} - \text{NOxA} \]

In the same way, the ADMA difference was calculated:

\[ \text{ADMA (V–A) difference} = \text{ADMAV} - \text{ADMA A} \]

All data are expressed as the means + SD. The unpaired t-test was used to compare the results of the 2 groups. The basal left coronary artery tone values of the left coronary artery in the patients with VSA were compared using ANOVA followed by a Fisher's protected least significant difference test. Correlations between the basal coronary artery tone and NOx (V–A) difference, the ergonovine dose and basal coronary artery tone, the NOx (V–A) difference and the ergonovine dose, and age and the ADMA concentration of ADMA were tested by linear regression analysis. Differences and correlations at \( p < 0.05 \) were considered statistically significant.

Results

Patients Characteristics (Table 1)

There were no significant differences between the coronary risk factors of the 2 groups.

Coronary Artery Diameters at Baseline and After ISDN

The baseline coronary artery diameters at baseline and the diameters after injection of ISDN in both groups are shown in Tables 2 and 3. The mean basal left coronary artery diameters at the proximal sites of the left coronary artery in the VSA patients were significantly smaller than
those of the corresponding sites in the control patients (LAD proximal: 2.67±0.59 vs 3.48±0.97 mm; LCx proximal: 2.28±0.55 vs 3.13±0.68 mm, p<0.01). After ISDN administration, however, there were no statistically significant differences between the 2 groups (LAD proximal: 3.32±0.78 vs 3.89±1.04 mm; LCx proximal: 3.05±0.68 vs 3.51±0.81 mm).

**Basal Coronary Artery Tone**

The basal left coronary artery tone values at the proximal and distal sites of left coronary artery in the VSA patients were significantly greater than those at the corresponding sites in control patients (Table 4). In addition, in the VSA group, the basal left coronary artery tone was significantly greater at the spastic site than at the other sites (proximal and distal sites of the LAD and LCx) (Table 4).

**Table 4 Basal Coronary Artery Tone in Control and VSA Groups**

<table>
<thead>
<tr>
<th>Spastic site</th>
<th>Control group</th>
<th>VSA group</th>
</tr>
</thead>
<tbody>
<tr>
<td>LAD Proximal</td>
<td>12±6</td>
<td>24±12†</td>
</tr>
<tr>
<td>LAD Distal</td>
<td>17±9</td>
<td>32±11†</td>
</tr>
<tr>
<td>LCx Proximal</td>
<td>12±6</td>
<td>35±22†</td>
</tr>
<tr>
<td>LCx Distal</td>
<td>21±13</td>
<td>34±18†</td>
</tr>
</tbody>
</table>

Values are expressed as mean±SD. *p<0.05 compared with other sites in the left coronary artery in VSA patients; †p<0.01 compared with the control patients; ‡p<0.05 compared with the control patients. LAD, left anterior descending coronary artery; LCx, left circumflex coronary artery; VSA, vasospastic angina.

**Relationships Between Basal Coronary Artery Tone, NOx (V–A) Difference and Ergonovine Dose**

We observed a significant negative correlation between the basal coronary artery tone at the spastic site and the NOx (V–A) difference (r=−0.596, p<0.05) in the VSA group (Fig 1), but not in the control. In addition, there was also a significant negative correlation (r=−0.667, p<0.01) between the basal coronary artery tone at the spastic site and the dose of ergonovine required to provoke spasm in the VSA group (Fig 2).

**Basal NOx and NOx (V–A) Difference**

The baseline concentrations of plasma NO2− and NO3− in the blood from the ostium of the NOxA and those from the NOxV are shown in Table 5. The plasma NOxA and NOxV concentrations of the 2 groups were not significantly different. The NOx (V–A) difference of the VSA group was apparently negative and differed significantly from that of the control group. Thus, the VSA patients showed a significant NOx imbalance in comparison with the control group.

**Basal ADMA and ADMA (V–A) Differences**

The basal plasma ADMA concentrations in the ostium of the left coronary artery (ADMAA) and the ADMA (V–A) differences of the 2 groups were not significantly different (Table 6). However, the plasma ADMA concentration of the VSA group in the coronary sinus (ADMAV) was higher than that of the control group.

**Plasma ADMA Concentration and Risk Factors**

The concentration of ADMA showed a positive correlation with age in all 32 patients (Fig 3), though no significant relationship was recognized between age and NOx (V–A) difference. However, there was no correlation between the concentration of ADMA and the NOx (V–A) difference.
plasma ADMA concentration and cholesterol concentration (total, low-density lipoprotein (LDL), high-density lipoprotein (HDL), or triglycerides; data not shown).

**Relationships Between NOx (V–A) Difference and ADMA (V–A) Differences**

We observed a significant negative correlation between the ADMA (V–A) difference and NOx (V–A) differences in the VSA group, but not in the control group (Fig 4).

**Discussion**

The major findings of this study are (1) the plasma concentration of ADMA in the coronary sinus was significantly higher in the VSA group than in the control group, (2) the NOx (V–A) difference (coronary sinus-arterial difference of NOx concentration) was apparently negative for the VSA group as compared with the control group, and (3) there was a significant negative correlation between the ADMA (V–A) difference and NOx (V–A) differences across the coronary circulation in patients with VSA, but not in the control. These findings suggest that the higher concentration of ADMA in the coronary circulation is associated with the reduced NO production in patients with VSA.

In our study, the mean plasma concentration of ADMA was 0.40 μmol/L, which is lower than that observed in another European study, but was similar to a value of approximately 0.51±0.01 μmol/L in Japanese patients reported by Miyazaki et al. We found that the concentration of ADMA was significantly related with aging, in good accordance with the report of Miyazaki et al. Therefore, our results regarding ADMA concentration are acceptable, although ethnic differences may contribute to the reported variations.

It has been demonstrated that the production of ADMA by human endothelial cells is regulated by S-adenosylhomocysteine-dependent methyltransferase, which is upregulated by native and oxidized LDL cholesterol. Recently, Kugiyama et al showed that the plasma concentrations of oxidized LDL were increased in patients with coronary spastic angina as compared with control patients and that these higher concentrations were a risk factor independent of other traditional risk factors for coronary spastic angina. Furthermore, Ogawa et al reported that the mean coronary sinus–arterial difference of the plasma concentration of antioxidantized LDL antibody was significantly higher in patients with coronary spastic angina than in either those with stable effort angina or the control subjects. In addition, several studies have indicated that the formation of oxidized LDL enhances agonist-induced coronary vascular contractions and reduces endothelium-dependent vasorelaxation. Therefore, oxidized LDL may be involved in the pathogenesis of coronary spasm via production of ADMA. Although we did not measure the concentration of oxidized LDL in the present study, those findings support our observation that the ADMA concentrations are increased in the coronary circulation of patients with VSA.

Interestingly, Böger et al demonstrated that ADMA increases superoxide radical production by cultured human endothelial cells in culture and promotes endothelial adhesion of human monocyteoid cells. It has been shown that oxidative stress or oxygen-derived free radicals may, at least in part, play a role in the abnormal coronary vasomotor reactivity and in anginal attacks in patients with VSA. Taking these considerations together, the findings indicate that in patients with VSA, oxidative stress is increased and this may be related to increased ADMA concentrations in the coronary circulation. The increased ADMA concentrations may, in turn, increase oxygen radical production, leading to a feed-forward loop between ADMA and superoxide radicals. Therefore, not only inhibition of NO synthase by ADMA, but also reduction of the biological activity of endothelium-derived NO, would appear to contribute to pathological conditions.

It has been suggested that the basal coronary tone is elevated at the spastic coronary arterial sites in VSA patients and that the coronary arteries of these patients are supersensitive to the vasodilator effects of nitrates. In the present study, we observed significantly higher basal coronary tone not only at the spastic site but also at the proximal and distal segments of the left coronary arteries in
VA patients. Moreover, there was a significant negative correlation between the basal coronary artery tone at the spastic site and the dose of ergonovine required to provoke spasm provocation. Our results are in agreement with those of other studies. The NOx difference in the control patients was close to zero, in agreement with our previous observations and those of another laboratory. Although a possible mechanism has been presented, the precise details remain unknown. However, decreased NO release from endothelium under the previously described circumstances may cause a negative NOx difference. Indeed, from endothelium under the previously described circumstances, the NOx (V–A) difference in VSA patients showed a negative correlation with the basal coronary artery tone, in good agreement with the results of our previous study. These results may assist in explaining the increased basal coronary artery tone in patients with VSA and the hyperreactivity to nitrate vasodilators not only of a localized segment, but also of the entire coronary tree in VSA patients. We consider that the increased coronary tone in the entire coronary artery tree of patients with VSA may be caused mainly by decreased reduced NO production in the coronary circulation and that the prominent marked increase in the basal tone of the spastic segments is clearly reflected in the decrease in the NOx concentration. Furthermore, the present study demonstrated that there was a significant negative correlation between the ADMA (V-A) difference and NOx (V-A) differences across the coronary circulation in the VSA group, but not in the control. Although the precise mechanism responsible for this decrease in the NOx concentration during coronary circulation remains unknown, the high concentration of the ADMA in the coronary circulation may be an important cause of reduced NO production in patients with VSA. However, dysfunction of endothelium would not be the sole cause of coronary vasospasm and that of smooth muscle should be also taken into consideration because tetrahydrobiopterin failed to prevent coronary spasm in patients with VSA, despite improvement of coronary endothelial function.

Study Limitations

One of the limitations of this study is that NOx and ADMA do not originate solely from the endothelium. In addition, we did not measure markers of oxidant stress in the coronary circulation and were unable to determine the contribution of ADMA to oxidative stress. Therefore, the present results need further investigation.

Conclusions

Patients with VSA had a negative NOx (V–A) difference in the coronary circulation, which was closely related to increased ADMA concentrations. Oxidative stress is increased in patients with VSA and thus may contribute to the higher concentration of the ADMA, establishing a feedforward loop. During coronary circulation, this mechanism would be operative in reducing the biological activity of endothelium-derived NO in spastic coronary arteries.

Acknowledgments

This work was partly supported by Grant for Promoted Research (S2001-13) and by Grant for Specially Promoted Research from Kanazawa Medical University.

References


